Geert Cauwenbergh - RXi Pharmaceuticals President CEO, Director

CEO

Dr. Geert Cauwenbergh, Ph.D. is the President, Chief Executive Officer, acting Chief Financial Officer, Director of RXI Pharmaceuticals Corporationrationration. He was appointed to the Board and was elected as President and Chief Executive Officer of the Company in April 2012. Prior to joining us, from June 2011 to April 2012, Dr. Cauwenbergh was active, through his consulting company Phases123 LLC, in advising various small biotech and healthcare companies. From July 2008 to June 2011, Dr. Cauwenbergh was the Chief Executive Officer of Rhei Pharmaceuticals HK Ltd, a Chinese company that licenses western drugs for development and commercialization in China, and Managing Director of the Center for Medical Innovation, a government subsidized center for translational medicine for the Belgian Region of Flanders. Barrier, which focused on dermatology drug development and commercialization, was acquired by Stiefel Laboratories, Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson Johnson, where he was employed for 23 years. As Vice President of Research and Development for Johnson Johnsons Skin Research Center, he was responsible for the worldwide research and development of all skin care products for the Johnson Johnson consumer companies. He is a member of the board of directors of Moberg Pharma AB, a Swedish pharmaceutical company. In February 2014, Dr. Cauwenbergh joined the board of directors of Phosphagenics Ltd., an Australian company focused on developing new transdermal delivery systems for pharmaceutical products since 2015.
Age 62
Tenure 9 years
Professional MarksPh.D
Phone508-767-3861
Webhttp://www.rxipharma.com
Cauwenbergh currently serves as chairman of the nominating and governance committee of Phosphagenics. In September 2011, Dr. Cauwenbergh also joined the board of directors of Cutanea Life Sciences, Inc., a wholly owned subsidiary of Maruho Company, LTD., which focuses on the development and commercialization of proprietary technologies to treat diseased and aging skin. In 2005,

RXi Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (96.79) % which means that it has lost $96.79 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (294.79) %, meaning that it created substantial loss on money invested by shareholders. RXi Pharmaceuticals' management efficiency ratios could be used to measure how well RXi Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Found 4 records

CEO Age

Sean BrowneXtant Medical Holdings
58
Wenbin JiangCytek Biosciences
60
Daniel GoldbergerXtant Medical Holdings
55
Christian HoggHUTCHMED DRC
48
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and is traded on Nasdaq Capital Markets. It employs 15 people. RXi Pharmaceuticals (RXII) is traded on NASDAQ Exchange in USA and employs 15 people.

Management Performance

RXi Pharmaceuticals Leadership Team

Elected by the shareholders, the RXi Pharmaceuticals' board of directors comprises two types of representatives: RXi Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RXi. The board's role is to monitor RXi Pharmaceuticals' management team and ensure that shareholders' interests are well served. RXi Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RXi Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Geert Cauwenbergh, President CEO, Director
Robert Bitterman, Director
Pamela Pavco, Chief Devel. Officer
Keith Brownlie, Director
Jonathan Freeman, Independent Director
Gerrit Dispersyn, Chief Development Officer
Curtis Lockshin, Director
Paul Dorman, Independent Director
Alexey Eliseev, Chief Business Officer
Tamara McGrillen, IR Contact Officer

RXi Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is RXi Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards RXi Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, RXi Pharmaceuticals' short interest history, or implied volatility extrapolated from RXi Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Consideration for investing in RXi Stock

If you are still planning to invest in RXi Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RXi Pharmaceuticals' history and understand the potential risks before investing.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
CEOs Directory
Screen CEOs from public companies around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios